Juho Jalkanen

Company: Faron Pharmaceuticals

Job title: Chief Operating Officer

Seminars:

Clinical Update on Bexmarilimab – the First-in-Class Anti-CLEVER-1 mAb 9:30 am

• FiH Phase I/II study showing extended survival in last line patients • Review biomarkers to identify responding patients • Outline future development plans based on the FiH Phase I/II resultsRead more

day: Day One